1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

AZ/Nektar constipation drug Movantik OK'd

 
• By Donna Young

Right on schedule, AstraZeneca and partner Nektar on 16 September won the FDA's approval to market Movantik (naloxegol), an oral peripherally active mu opioid receptor antagonist (PAMORA), as a treatment for opioid-induced constipation (OIC) in adults with chronic non-cancer pain.

Right on schedule, AstraZeneca and partner Nektar on 16 September won the FDA's approval to market Movantik (naloxegol), an oral peripherally active mu opioid receptor antagonist (PAMORA), as a treatment for opioid-induced constipation (OIC) in adults with chronic non-cancer pain.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

AstraZeneca’s Truqap Trips Up In Prostate Cancer Study

 
• By Kevin Grogan

The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.